Darin Lippoldt Sells 1,979 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 1,979 shares of the stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $79.36, for a total transaction of $157,053.44. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Darin Lippoldt also recently made the following trade(s):

  • On Friday, December 28th, Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.00, for a total transaction of $1,142,775.00.
  • On Thursday, December 28th, Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.00, for a total transaction of $1,142,775.00.
  • On Friday, December 8th, Darin Lippoldt sold 2,955 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.00, for a total transaction of $221,625.00.
  • On Monday, December 4th, Darin Lippoldt sold 6,279 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.04, for a total transaction of $471,176.16.
  • On Wednesday, November 15th, Darin Lippoldt sold 9,900 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $73.05, for a total transaction of $723,195.00.

Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $81.73 on Friday. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences, Inc. has a one year low of $38.43 and a one year high of $83.57.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period in the prior year, the business earned ($0.43) earnings per share. sell-side analysts forecast that Neurocrine Biosciences, Inc. will post -1.66 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company grew its position in Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares during the last quarter. Comerica Bank bought a new position in Neurocrine Biosciences during the third quarter valued at approximately $210,000. Trexquant Investment LP bought a new position in Neurocrine Biosciences during the third quarter valued at approximately $246,000. World Asset Management Inc bought a new position in Neurocrine Biosciences during the third quarter valued at approximately $246,000. Finally, Stifel Financial Corp bought a new position in Neurocrine Biosciences during the third quarter valued at approximately $246,000.

NBIX has been the topic of several recent research reports. Robert W. Baird reaffirmed a “buy” rating and set a $84.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 3rd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $76.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, October 25th. Deutsche Bank reaffirmed a “buy” rating and set a $79.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Jefferies Group reaffirmed a “buy” rating and set a $69.00 price objective (up from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. Finally, Oppenheimer upped their price objective on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $81.13.

TRADEMARK VIOLATION NOTICE: “Darin Lippoldt Sells 1,979 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/01/06/darin-lippoldt-sells-1979-shares-of-neurocrine-biosciences-inc-nbix-stock.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

What are top analysts saying about Neurocrine Biosciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neurocrine Biosciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit